Effects of the Medial Longitudinal Slope on Clinical Parameters and Acceleration Impacts During Gait
Effects of the Medial Longitudinal Slope on Clinical Parameters and Acceleration Impacts During Gait
The objective of this clinical trial is to compare the effects of the geometry of the medial longitudinal arch (MLA) of the insole on acceleration impacts during gait, measured using an accelerometry system, in patients with pain related to the presence of a pronated foot morphotype. The main questions it aims to answer are:
Is the slope of the medial longitudinal arch of the orthotic treatment a factor that reduces the peak tibial accelerometry in a symptomatic foot with a medially oriented subtalar joint axis? To assess the predictive effect of changes in acceleration impacts on the patient's painful symptoms.
The researchers will compare the MLA of the insole taken in a standing position with the MLA of the insole taken in a sitting position (the treatment applied in routine clinical practice) to evaluate if changing the slope of the MLA generates changes in the tibial acceleration impacts.
The participants:
Must use the insoles to carry out their daily activities, except for sleeping or bathing.
The first review of the orthotic treatment will be conducted 3 months after the treatment initiation.
Study Population The study population will consist of patients treated from June 2024 onwards at the Pathology and Orthopedics Service of the University Clinic of Podiatry at Complutense University of Madrid. All participants will be informed beforehand about the characteristics, objectives, and methodology of the present study and must consent by signing the informed consent form, which complies with the regulatory legislation under the Organic Law on Data Protection and guarantee of digital rights 3/2018, of December 5, and Law 41/2002, of November 14, which regulates the patient's autonomy and rights and obligations in terms of information and clinical documentation. (Organic Law 3/2018) recognizes a series of rights for citizens, such as the right of access, rectification, cancellation, and opposition to their personal data, the right to limit the treatment of incorrect data, request a copy, or transfer the data provided for the study to a third party (portability), to the extent that they are applicable.
Sample Size A sample size is estimated for the comparison of two independent proportions at a 5% significance level, an 80% statistical power, and a two-tailed test. Since no published study has evaluated exactly the angulation in both sitting and standing positions under the same conditions, reference values are not precisely known. However, it is estimated that the main outcome variable, peak acceleration, will behave similarly. There is a threshold for this variable at 8 g, such that a peak above this is a risk factor for developing lower limb pathology. In our study, it is expected that only 5% of patients in group A will have a peak above 8 g, while 30% of patients in group B will have a peak above 8 g. Considering these factors and anticipating a 15% possible dropout rate, a minimum sample size of 37 patients per group is needed to achieve the main objective, totaling 74 patients.
Analyzed Variables and Data Collection Procedures Patient data recording will begin on the first consultation day after conducting the relevant screening and fulfilling the established inclusion and exclusion criteria. All data will be collected in a data collection notebook, with each patient assigned an identification code to safeguard compliance with the Organic Law on Data Protection and guarantee of digital rights 3/2018, of December 5, and Law 41/2002, of November 14, which regulates the patient's autonomy and rights and obligations in terms of information and clinical documentation.
Dependent Variables
Outcome Variables:
Primary Variable: Maximum tibial acceleration (g). Continuous quantitative variable (m/s²).
Secondary Variables:
Maximum head acceleration (g). Continuous quantitative variable (m/s²). Magnitude of head acceleration (g). Continuous quantitative variable (m/s²). Head acceleration ratio (38-70) (g/s). Continuous quantitative variable (m/s²). Magnitude of tibial acceleration (g). Continuous quantitative variable (m/s²). Tibial acceleration ratio (30-70) (g/s). Continuous quantitative variable (m/s²).
Impact attenuation (%). Continuous quantitative variable (m/s²). Step length (cm). Continuous quantitative variable (cm). Stride frequency (Hz). Continuous quantitative variable (Hz). Independent Variables Treatment Variables Demographic Variables - Covariates Clinical Variables Variables related to the wear of the orthotic treatment Study Planning Patient Recruitment Start: June 2024 Estimated End of Patient Recruitment: December 2024 Treatments Treatment A: A plantar orthosis made of 4.5 mm polypropylene with BIO at the necessary degrees according to the patient's biomechanical characteristics, MLA that replicates the geometry and slope of the MLA in the sitting position (unloaded). Duration of treatment: 12 weeks.
Treatment B: A plantar orthosis made of 4.5 mm polypropylene with BIO, and the MLA taken from the patient replicates the geometry and slope of the MLA in the standing position (loaded). Duration: 12 weeks.
Patient Visit Planning VISIT 1: Inclusion in the study. VISIT 2: Treatment delivery. Acceleration data will be recorded using an Xsens DOR accelerometry system (Xsens, Enschede, Netherlands: total mass: 10.9 g; dimensions 36x30x11 mm, range ± 16 g), consisting of 3 triaxial accelerometers. Two accelerometers will be placed on the anteromedial surface of the distal end of both tibias, 3 cm superior to the medial malleolus where the first uniform/flat surface is present, with the vertical axis of the accelerometer parallel to the tibial vertical axis; the third accelerometer will be placed on the forehead with the tibial vertical axis; and the third accelerometer will be placed on the forehead with the accelerometer's vertical axis perpendicular to the ground. All accelerometers will be placed by a single researcher (ASR). Patients will wear sports clothing, shorts, and neutral Reebok Classics sneakers. Before starting the test, the patient will walk freely around the room for 5 minutes to get used to the shoes and/or orthosis. Then, the patient will be instructed to walk at a "comfortable and safe" speed along a straight 12 m corridor, performing a total of 10 series. Accelerometry data will be recorded during the central 8 meters, with 2 meters at the start and 2 meters at the end designated as acceleration and deceleration zones, respectively, to avoid their effects. The speed of each series will be recorded using a photo-cell system (Chronojump Boscosystem), but it will not be controlled to avoid altering the natural gait pattern. The average speed of all series for each participant will be calculated, and those not within ±5% of each participant's average speed will be discarded to minimize the effect of gait speed on acceleration impacts.
After this second visit, orthoses A and B will be distributed randomly, dividing the sample into two equal halves, so that patients will use the assigned orthosis daily for 12 weeks.
VISIT 3: 12 weeks after starting the treatment.
Inclusion Criteria:
Subjects of both sexes, aged over 18 years. Patients with painful symptoms in the lower limb associated with a Foot Posture Index (FPI-6) score > 5, indicative of foot pronation position.
Navicular Drop Test > 10 mm. Subjects with painful symptoms associated with foot pronation position. Signed informed consent explaining the study's characteristics and objectives.
Exclusion Criteria:
Subjects presenting at least one of the following conditions will be excluded:
Previous diagnosis of neurological or rheumatological systemic disease. History of foot or ankle surgery resulting in limitations in the mobility of the subtalar, midtarsal, or metatarsophalangeal joints.
History of leg, ankle, or foot fracture resulting in limitations in the mobility of these structures.
Lower limb morpho-functional alteration: clinical asymmetry greater than 5 mm, presence of genu varum, genu valgum with a difference of more than 2° femoro-tibial between limbs, internal or external femoral torsion.
Cognitive impairment preventing understanding of the study's objectives and compliance with participation guidelines.
Patients unable to walk independently due to musculoskeletal injury in the lower limbs within the last 6 months.
Currently receiving any analgesic treatment for the lower limbs at the time of intervention.